Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Shares Sold by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. lowered its stake in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 22.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,750,000 shares of the company's stock after selling 500,000 shares during the period. Alyeska Investment Group L.P. owned about 1.69% of Unicycive Therapeutics worth $1,390,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of UNCY. Virtu Financial LLC grew its holdings in shares of Unicycive Therapeutics by 566.8% in the third quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock valued at $30,000 after purchasing an additional 62,881 shares during the period. Northern Trust Corp raised its position in Unicycive Therapeutics by 142.4% in the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock valued at $46,000 after purchasing an additional 34,183 shares during the period. XTX Topco Ltd lifted its stake in shares of Unicycive Therapeutics by 142.2% in the 4th quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock valued at $136,000 after purchasing an additional 100,679 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Unicycive Therapeutics by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock worth $417,000 after purchasing an additional 122,089 shares during the last quarter. Finally, Acuta Capital Partners LLC lifted its position in Unicycive Therapeutics by 16.4% in the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock valued at $1,829,000 after buying an additional 323,801 shares during the last quarter. 40.42% of the stock is currently owned by institutional investors and hedge funds.

Unicycive Therapeutics Stock Performance

UNCY stock traded up $0.02 during trading on Monday, reaching $0.57. 380,680 shares of the company were exchanged, compared to its average volume of 1,461,532. The stock's 50 day moving average price is $0.59 and its 200 day moving average price is $0.61. The company has a market cap of $69.12 million, a P/E ratio of -0.59 and a beta of 2.14. Unicycive Therapeutics, Inc. has a 52-week low of $0.20 and a 52-week high of $1.16.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.13). As a group, equities research analysts forecast that Unicycive Therapeutics, Inc. will post -0.23 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on UNCY shares. Guggenheim assumed coverage on shares of Unicycive Therapeutics in a research note on Monday, April 21st. They issued a "buy" rating and a $6.00 price target on the stock. HC Wainwright reissued a "buy" rating and set a $7.50 target price on shares of Unicycive Therapeutics in a research report on Friday, April 11th.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.